The cardio-protective properties of ncx-6550, a nitric oxide donating pravastatin, in the mouse

Microcirculation

Volumn 17, Issue 6, 2010, Pages 417-426

  Di Filippo, Clara ^a   Monopoli, Angela ^b   Ongini, Ennio ^b   Perretti, Mauro ^c   D'Amico, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Nicox Research Institute   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

infarction; mouse; myocardium; Ncx 6550; pravastatin

Indexed keywords

(1ALPHA,2ALPHA,6ALPHA,8BETA,8ALPHA) 1,2,6,7,8,8A HEXAHYDRO BETA,DELTA,6 TRIHYDROXY 2 METHYL 8 (2 METHYL 1 OXOBUTOXY) 1 NAPHTHALENEHEPTANOIC ACID 4 (NITROXYBUTYL ESTER); HEME OXYGENASE 1; INTERLEUKIN 1BETA; NCX 6550; NITRATE; NITRIC OXIDE DONOR; NITRITE; PRAVASTATIN; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE HEART RATE INDEX; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART PROTECTION; HEART RATE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; TISSUE LEVEL;

ANIMALS; CARDIOTONIC AGENTS; HEME OXYGENASE-1; HEMODYNAMICS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-1BETA; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NITRATES; NITRIC OXIDE DONORS; NITRITES; PRAVASTATIN; TROPONIN I;

MUS;

EID: 77955264736     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/j.1549-8719.2010.00040.x     Document Type: Article

References (37)

1. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 24 : 225 248, 2003.
2. Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 18 : 32 39, 2006.
3. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57 : 640 651, 2004.
4. Coelho-Filho OR, De Luca IM, Tanus-Santos JE, Cittadino M, Sampaio RC, Coelho OR, Hyslop S, Moreno JH. Pravastatin reduces myocardial lesions induced by acute inhibition of nitric oxide biosynthesis in normocholesterolemic rats. Int J Cardiol 79 : 215 221, 2001.
5. D'Amico M, Di Filippo C, La M, Solito E, McLean PG, Flower RJ, Oliani SM, Perretti M. Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment. FASEB J 14 : 1867 1869, 2000.
6. Dever G, Spickett CM, Kennedy S, Rush C, Tennant G, Monopoli A, Wainwrigth CL. The nitric oxide-donating pravastatin derivative, NCX-6550 (1S-[1α(βS*,;S*),2α,6α,8β-(R*), 8aα]]-1,2,6,7,8,8a-hexahydro-β,6-trihydroxy-2-methyl-8-(2-methyl-1- oxobutoxy)-1-naphtaleneheptanoic acid 4-(nitrooxy)butyl ester), reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice. J Pharmacol Exp Ther 320 : 419 426, 2007.
7. Di Filippo C, Rossi F, Rossi S, D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 75 : 453 459, 2004.
8. Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella P, Giugliano D, Rossi F, D'Amico M. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 54 : 803 810, 2005.
9. Emanueli C, Monopoli A, Kraenkel N, Meloni M, Gadau S, Campesi I, Ongini E, Madeddu P. Nitropravastatin stimulates reparative neovascularization and improves recovery from limb ischaemia in type-1 diabetic mice. Br J Pharmacol 150 : 872 882, 2007.
10. Endres M. Statins: potential new indications in inflammatory conditions. Atheroscler 7 : 31 35, 2006.
11. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53 : 31 47, 2002.
12. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13 : 1877 1893, 2006.
13. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 58 : 88 111, 2008.
14. Fukuda H, Sawa Y, Kadoba K, Taniguchi K, Shimazaki Y, Matsuda H. Supplement of nitric oxide attenuates neutrophil-mediated reperfusion injury. Circulation 92 : 413 416, 1995.
15. Guo JP, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 75 : 77 84, 1994.
16. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 : 7 22, 2002.
17. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D, Huang PL, Lefer DJ. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 276 : H1567 H1573, 1999.
18. Jones SP, Trocha AD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol 21 : 2059 2064, 2001.
19. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 121 : 951 957, 1991.
20. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure mechanisms and clinical trials. J Card Fail 12 : 664 674, 2006.
21. Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Ann Pharmacother 36 : 751 757, 2002.
22. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 291 : 864 1870, 2004.
23. La M, D'Amico M, Bandiera S, Di Filippo C, Oliani SM, Gavins FN, Flower RJ, Perretti M. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. FASEB J 15 : 2247 2256, 2001.
24. La M, Tailor A, D'Amico M, Flower RJ, Perretti M. Analysis of the protection afforded by annexin 1 in ischemia-reperfusion injury: focus on neutrophil recruitment. Eur J Pharmacol 429 : 263 278, 2001.
25. Lefer A, Campbell B, Shin Y-K, Scalia R, Hayward R, Lefer D. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 : 178 184, 1999.
26. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, Huang PL, Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am J Physiol 276 : H1943 H1950, 1999.
27. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, Lefer AM. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15 : 1454 1456, 2001.
28. Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7 : 149 164, 2002.
29. Masini E, Vannacci A, Marzocca C, Pierpaoli S, Giannini L, Fantappié O, Mazzanti R, Mannaioni PF. Heme oxygenase-1 and the ischemia-reperfusion injury in the rat heart. Exp Biol Med (Maywood). 228 : 546 549, 2003.
30. Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A, Del Soldato P, Ignarro LJ. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 101 : 8497 8502, 2004.
31. Peterson SJ, Frishman WH, Abraham NG. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev. 17 : 99 111, 2009.
32. Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A, Ongini E, Semeraro N, Colucci M, Gresele P. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost 3 : 2554 2562, 2005.
33. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apoE deficient mice. Circulation 103 : 2598 2603, 2001.
34. Scalia R. Statins and the response to myocardial injury. Am J Cardiovasc Drugs 5 : 163 170, 2005.
35. Tanaka T, Ozaki K. Inflammation as a risk factor for myocardial infarction. J Hum Genet 51 : 595 604, 2006.
36. Van der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71 : 443 454, 2006. (Pubitemid 44107859)
37. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274 : 131 136, 1995.